Takeda latest to welcome UK's stance on EMA post-Brexit

6 March 2018

On Friday, the UK Prime Minister Theresa May finally provided some clarity on what she wants the UK’s future relationship with the European Medicines Agency (EMA) to look like as part of her “Road to Brexit” speech.

London might be losing the privilege of being the host city of the EMA – with the headquarters set to move to Amsterdam next year – but Mrs May stressed that she wants to explore the chance for the UK to remain part of the agency in her upcoming negotiations with the European Union (EU).

"The investment from both large and small companies confirms that the UK will continue to be a global leader in pharmaceuticals"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK